Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Intestinal and Multivisceral Transplantation Treatment & Management

  • Author: Seigo Nishida, MD, PhD; Chief Editor: Stuart M Greenstein, MD  more...
Updated: Jan 06, 2016

Medical Therapy

The role of TPN in short bowel syndrome is established, and long-term TPN is the treatment of choice for these patients because of its well-documented long-term safety.[18] A subset of patients with short bowel syndrome cannot tolerate TPN because of frequent episodes of catheter-associated sepsis, catheter-associated vascular thrombosis, or TPN-induced cholestasis. These patients need intestinal or multivisceral transplantation.


Surgical Therapy

Recipient characterization

At the University of Miami, a total of 349 transplantations were performed in 309 patients from December 1994 to May 2012. The number of cases per year has increased since 1994 (see following image). Sex distribution was approximately equal, with 154 males (50%) and 155 females (50%).

Number of transplants. Number of transplants.

In terms of age, 187 (61%) were pediatric recipients, and 122 (39%) were adult recipients (see following image). Also, 80 patients (26%) received isolated intestinal transplantation, 36(12%) received combined liver and intestinal transplantation, 28 (9%) received modified multivisceral transplantation and 165 (53%) received multivisceral transplantation.

Intestinal transplantation in adult and pediatric Intestinal transplantation in adult and pediatric patients.


The donor population consisted of 177 (57%) males and 132 (43%) females. Donor age is summarized in the following image. Donor selection in intestinal transplantation is critical. Donors should be in the same ABO blood group as the recipient and should have negative serology results for human immunodeficiency virus (HIV) and hepatitis viruses. CMV status of the donor has no influence on selection criteria at the University of Miami. Donor size is an important consideration because most recipients have loss of domain resulting from massive intestinal resection. Donors are usually smaller than the recipients to accommodate the small abdominal compartment that accompanies short bowel syndrome.

Donor age. Donor age.

Preoperative Details

Before organ procurement, all the teams, including the liver transplantation team, the kidney transplantation team, the pancreas transplantation team, and the intestinal transplantation team, must discuss the procedure with any organ procurement surgeons present who are unfamiliar with intestinal graft procurement. Each team present has an interest in the specific organ they are recovering, and this discussion addresses any concerns they may have.

Patients referred for intestinal transplantation are evaluated by a multidisciplinary team with representatives from the following specialties: transplant surgery, gastroenterology, nephrology, cardiology, radiology, nursing, psychology, and social work. Pertinent information for evaluation of candidates for intestinal transplantation includes a detailed medical and surgical history, radiologic mapping of GI anatomy and radiologic assessment of the patency of the 6 major routes of central venous access (eg, internal jugular, subclavian, femoral), and assessment of liver, renal, and cardiac function.

Precise information regarding previous abdominal surgery and the length of remaining intestine is critical. Liver function test results must be carefully evaluated for derangements that suggest the need for biopsy evaluation. If significant fibrosis, macrosteatosis, or cirrhosis is present on liver biopsy, then liver transplantation is necessary. Evaluation of renal function is critical because of the need for long-term use of tacrolimus postoperatively.


Intraoperative Details

Donor operation

The basic principles of intestinal and multiple intra-abdominal organ procurement have evolved over the past decade, and the operative techniques have been described in detail.[9, 19] If the intestinal graft is to be transplanted alone, the portal vein is cut above the confluence of the superior mesenteric and splenic veins, and the SMA is cut with an aortic cuff. If a right replaced hepatic artery is present, the SMA is cut distal to the takeoff of the replaced artery. In multivisceral grafts, both the celiac and superior mesenteric arteries are procured, with the thoracic and abdominal aorta proximal to the origin of the renal arteries. The graft is flushed with 4°C University of Wisconsin solution via a cannula placed in the distal aorta of the donor.

Cold ischemic time is minimized by initiating the recipient operation as soon as the donor graft is harvested. The mean cold ischemic time at the University of Miami is 480 minutes, with 13 hours being the maximum ischemic time to date. The portal vein and SMA are dissected and are prepared for isolated transplantation at the back table prior to implantation in the recipient. The composite graft, including thoracic aorta, abdominal aorta, and vena cava, is dissected and prepared for liver-intestinal or multivisceral transplantation.

Recipient operation

Three variations of transplants are performed for patients with intestinal failure (see following images). In isolated intestinal transplantation, only the small intestine is transplanted, and the donor SMA is anastomosed to the recipient SMA or aorta, with or without an interposition graft from the donor iliac or carotid arteries. The arterial graft can be anastomosed to the supraceliac or infrarenal aorta of the recipient.

Isolated intestine transplantation. Isolated intestine transplantation.
Liver and intestine transplantation. Liver and intestine transplantation.
Liver, intestine, and pancreas transplantation. Liver, intestine, and pancreas transplantation.
Multivisceral transplantation. Multivisceral transplantation.

Portal venous anastomosis is performed using either portal or systemic drainage. In portal drainage, the portal vein can be anastomosed to the recipient superior mesenteric vein, to the confluence of the superior mesenteric and splenic veins, or to the side of the recipient portal vein. If access to the recipient portal system is difficult, systemic drainage can be used. In systemic drainage, the donor portal vein is anastomosed to the recipient vena cava in an end-to-side fashion. No survival advantage and no difference with regard to metabolic and immunologic consequences have been reported between portal and systemic drainage.

Combined liver and intestinal transplantation includes the liver and the intestine as a composite graft. The donor and recipient aortas are anastomosed end-to-side with an interposition aortic graft. The vena cava anastomosis is usually performed end-to-side with the recipient hepatic veins for venous outflow (piggyback technique).

Multivisceral transplantation includes the stomach, pancreas, and intestine, with or without the liver or kidney. The arterial and vena caval anastomoses are the same as for combined liver-intestinal transplantation. The proximal end of the isolated intestinal and combined liver-intestinal transplantation is anastomosed side-to-side to the distal end of the native recipient intestine. In multivisceral transplantation, the proximal anastomosis is performed between the donor stomach and the recipient esophagus. A catheter for enteral feeding is placed in the jejunum. The distal end of the transplanted intestine is exteriorized as a stoma to decompress the bowel and to monitor the graft for signs of rejection. The distal part of the intestinal graft just proximal to the ileostomy is anastomosed to recipient colon (if present).

Graft size considerations are important in intestinal transplantation. If the graft is large for the shrunken abdomen of the recipient, resection of intestine and/or liver is performed. Abdominal closure may require mesh or staged approximation. Skin flaps, muscle flaps, or synthetic mesh can be used in cases where significant size discrepancies exist.

Defects of the abdominal wall are an important surgical issue for the patient with multiple surgeries. Abdominal wall transplants have been performed for these patients. The iliac artery and vein were used for vascular anastomosis. Cadaveric fascia grafts have been used for abdominal closure.


Postoperative Details

Patients require intensive hemodynamic monitoring for the first few days after surgery. Patients arrive from the operating room to the intensive care unit intubated with a central line, arterial line, Foley catheter, nasogastric tube, and an ostomy bag. If venous access permits, the patient also has a Swan-Ganz catheter. The patient remains in the intensive care unit for several days because of the need for careful fluid management due to massive third spacing that occurs in the peritoneal cavity immediately following intestinal graft reperfusion.[20] The recipient is at risk for pulmonary edema during this early period.

Infectious prophylaxis is an important part of the postoperative care of intestinal transplant recipients. Antifungal prophylaxis with a liposomal preparation of amphotericin and broad-spectrum antibiotics is administered for the early postoperative period. Gut decontamination with amphotericin B, gentamicin, and kanamycin is administered until reasonable enteral feeding volumes are achieved. CMV was a formidable barrier to successful intestinal transplantation prior to the initiation of good prophylaxis.[21] Recipients receive a prophylactic regimen consisting of intensive anti-CMV globulin (CytoGam) treatment and intravenous ganciclovir. CytoGam is administered at a dose of 100 mg/kg every other day for 30 days, followed by 150 mg/kg every 2 weeks for 3 months. No patients on this protocol have had serious problems with CMV. This protocol has allowed the use of CMV-positive donors for all recipients.

Enteral feedings are started 4-6 days after transplantation via the gastrojejunostomy tube to maintain mucosal integrity and to preserve the gut permeability barrier. Diluted Vivonex is started at a low rate and increased first in volume and then in strength until the daily energy goal for the patient is met. Oral feedings are started at 2 weeks postoperatively if intestinal function is adequate. TPN is slowly tapered and gradually discontinued once the patient can sustain total energy intake with enteral feedings.


The development of new immunosuppressive agents has been a major factor in the improvement in survival rates following intestinal and multivisceral transplantation. Tacrolimus and steroids have been the first-line immunosuppressive agents in intestinal transplantation since 1990. Tacrolimus is administered to achieve trough levels of 15-20 ng/mL via oral or intravenous routes. The interleukin (IL)–2 receptor antagonist daclizumab (Zenapax) was used for induction immunosuppression at the University of Miami beginning in 1998. Daclizumab was withdrawn from the United States market because of diminished use and emergence of other effective therapies.

Sirolimus is another new immunosuppressive agent that is proving to be invaluable in intestinal and multivisceral transplantation. Sirolimus is a macrolide antibiotic that binds to FK-binding protein 12 and inhibits T-cell proliferation.[22] Sirolimus is not nephrotoxic and, as such, is invaluable for patients who have poor renal function postoperatively. In addition, the authors have used sirolimus in conjunction with tacrolimus to minimize renal adverse effects caused by tacrolimus.

Recently, the authors have started using an anti-CD52 antibody alemtuzumab (Campath) as an addition to the induction immunosuppression protocol.[23, 12] Preliminary results are satisfactory. However, determining whether alemtuzumab will have a long-lasting role in intestinal and multivisceral transplantation is not yet possible. Tymoglobuline is also used for pediatric patients. If DSA levels are high, plasmapheresis, anti-CD20 antibody, and bortizmab may be used for controlling humoral rejection.

Monitoring for and treatment of rejection

The addition of routine early postoperative zoom video endoscopy (ZVE) has contributed to an improvement in survival rates following intestinal transplantation at the University of Miami.[24] Surveillance ZVE and biopsy are started on the third postoperative day and continued twice weekly for the first postoperative month. ZVE and biopsy are then performed weekly for 2-4 months postoperatively. After the fourth postoperative month, ZVE is initiated based on clinical signs of rejection. Clinical signs of rejection are increased ostomy output (>40 mL/kg/d), fever, and abdominal pain. ZVE and biopsy are initiated at any point in the postoperative course when these signs are present. ZVE is able to magnify the image of the mucosa 100 times so that individual microvilli can be observed.

The authors believe that the ZVE minimizes sampling errors because more accurate identification of the most severely injured areas of mucosa is possible. The ZVE also allows identification of rejection at a much earlier stage than conventional endoscopy; thus, the incidence of graft loss due to severe rejection has decreased greatly in the authors' series.

Since initiation of the ZVE protocol, the authors improved the timing of treatment of rejection and prevention of overimmunosuppression. Mild or moderate intestinal rejection is treated with steroids and usually resolves. If moderate rejection does not immediately respond to increased steroids, OKT3 therapy is initiated. OKT3 is effective for the treatment of moderate rejection but is only marginally effective in reversing severe rejection. Early detection of rejection to prevent severe rejection is essential to achieving long-term graft survival.

The monitoring of intestinal transplants for rejection has room for improvement. Most notably absent is the presence of a serum marker or profile for rejection. Intestinal fatty acid binding protein was extensively tested without success. Serum citrulline levels are now under examination as an early marker for graft rejection.[25] The early results suggest that using citrulline levels to diagnose intestinal graft rejection has significant promise.

Wireless capsule endoscopy may be another option to monitor the entire small bowel tract in order to monitor acute rejection and inflammation without any delay.

Citrulline may be used for monitoring the rejection. Each patient has different value of the citrulline. However, citrulline can be very helpful for long term monitoring of the patient rejection.

Association between DSA and acute rejection and resolution in small bowel and multivisceral transplantation has been observed.[26]



Immunosuppression and rejection monitoring are the main issues after the transplantation.

Tacrolimus (Prograf) levels are checked daily for a month. Then, blood levels are checked twice a week for another month and then once a week depending on the blood level and condition.

Steroids are tapered slowly over several months.

Rejection monitoring by endoscopy is performed twice weekly for the first postoperative month and then weekly for postoperative months 2-4 depending on the clinical situation. After that, periodic endoscopy is performed depending on the clinical signs of rejection.




Rejection occurs in nearly all recipients of intestinal and multivisceral transplants.[27] Onset is usually manifested by high ostomy output (>40 mL/kg/d), fever, ileus, and abdominal pain. Prior to the initiation of routine surveillance with ZVE and biopsy, delays in diagnosis were frequent, and graft loss due to severe rejection was commonplace. Since the introduction of this protocol, incidence of severe rejection is very unusual. ZVE allows examination of the intestinal mucosa for villus height, shape of microvilli tips, background erythema, villous bleeding, and friability (see following image). Rejection in the early stages examined by ZVE reveals villous blunting, background erythema, and mucosal friability. The authors have developed a ZVE scoring system that is undergoing evaluation for clinical use as a tool to grade rejection.

Endoscopic view of small-bowel graft is shown. Vie Endoscopic view of small-bowel graft is shown. Views A and D are normal; views B and E show moderate rejection; and views C and F indicate severe rejection.

Mild and moderate rejection is treated with steroid pulses. Mild rejection only rarely does not respond to steroids, whereas moderate rejection sometimes requires a course of OKT3 to be reversed. In the authors' experience, severe rejection is irreversible, resulting in graft loss in all patients in the authors' series. Maintaining Prograf trough levels in the 15- to 20-ng/mL range during and following episodes of rejection is important. In patients whose renal function does not tolerate Prograf levels of 15-20 ng/mL, sirolimus can be added to provide further T-cell immunosuppression.

In early experimental studies, a survival advantage to transplanting the liver with the intestine was shown.[28] Clinical results have shown that the opposite is true (ie, recipients of isolated intestinal transplants fare better than those receiving liver-intestinal and multivisceral transplants).[29] The survival rate in isolated intestinal transplantation is better than in liver-intestinal or multivisceral transplantation at the University of Miami. Isolated liver transplantation in infants with TPN-associated liver disease has recently been considered in selected cases.[30] .


Infection has been a primary component in the failure of clinical intestinal transplantation. Keys to minimizing infection include rigorous CMV prophylaxis, fastidious central line care, early central line removal, and routine fungal prophylaxis during periods of most intense immunosuppression. The common bacterial pathogens are Escherichia coli, Enterococcus faecium, Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus, Klebsiella, and Proteus species.[31] The most commonly encountered fungal pathogens are Candida and Aspergillus species.

Epstein Barr virus (EBV) is a common problem in clinical intestinal transplantation. Prophylaxis with CytoGam and ganciclovir has reduced the incidence of early EBV infection in intestinal transplantation. EBV transformation and the development of posttransplant lymphoproliferative disorder are particularly common in recipients of intestinal transplants. The development of anti-CD20 antibody (Rituximab) has provided a badly needed therapy for intestinal recipients with posttransplant lymphoproliferative disorder.

Adenovirus and respiratory virus are 2 viral pathogens that are encountered in pediatric recipients of intestinal transplants. Reductions in immunosuppression and ribavirin can sometimes result in patient recovery from these 2 difficult viral infections.

Surgical complications

Postoperative bleeding is the most common surgical problem in intestinal transplantation. Most of the patients have borderline liver function and bleeding tendency.

Meticulous surgical hemostasis is necessary. Vascular problems are unusual following intestinal transplantation. The authors have had 3 cases of arterial graft infection, with rupture and death in each case. Attention must be paid to aseptic procedures during the donor and recipient operations. Large-volume antibiotic irrigation is applied in the operating room in an attempt to minimize this complication. Leakage at the intestinal anastomosis has occurred twice. In one case, the patient was explored and the defective anastomosis (esophagogastrostomy) was redone. In another case, the fistula between the colon and the jejunum closed itself. The patients did well in both cases.

Renal failure

Recipients of intestinal and multivisceral transplants often have renal impairment prior to transplant and are then started on multiple nephrotoxic agents (tacrolimus, amphotericin, and vancomycin are the common ones). The addition of sirolimus to decrease Prograf dosing can have renal-sparing effects. Liposomal amphotericin may possibly minimize the nephrotoxic effects of amphotericin. If frank renal failure occurs, continuous venovenous hemodialysis or intermittent hemodialysis may be necessary until the kidneys recover. Careful attention to the use of nephrotoxic agents and close follow-up with a nephrologist are mandatory for the successful management of these critically ill patients.


Outcome and Prognosis

Patient and graft survival

The International Registry for Intestinal Transplantation reports that graft and patient survival rates have improved, with a 69% 1-year patient survival rate and a 55% graft survival rate since 1995.[27] Trevizol et al studied the procedure over a 5-year period and reported a 1-year patient survival rate of 80%, but survival decreases after the first year to less than 70%.[32]

At the University of Miami, the 1-year survival rate of patients who received transplantations in 1994 was 75%, and the graft survival rate was 68%. Since 1998, the 1-year patient survival rate has been 84%, and the graft survival rate, 72% (see following image). In 1998, we introduced the ZVE and biopsy protocol and daclizumab induction therapy for all intestinal and multivisceral recipients. The authors attribute the improvement in patient and graft survival rates since 1998 to these two modifications in the program. Daclizumab was withdrawn from the United States market in 2009 because of diminished use and emergence of other effective therapies.

Patient survival of isolated intestinal transplant Patient survival of isolated intestinal transplantation.
Patient survival of 3 types of intestinal transpla Patient survival of 3 types of intestinal transplantation.

The authors are certain that earlier referral of the patients for intestinal transplantation yields improved survival results. The authors' results do show that isolated transplantation is preferable to combined liver-intestinal or multivisceral transplantation from a survival standpoint. Posttransplant prognosis is also improved when transplantation is performed prior to the onset of liver failure and prior to the exhaustion of all routes of vascular access.

Causes of death included the following:

  • Sepsis after rejection
  • Respiratory failure
  • Sepsis
  • Multiple organ failure
  • Arterial graft infection
  • Aspergillosis
  • Posttransplantation lymphoproliferative disorder
  • Intracranial bleeding
  • Fungemia
  • Chronic rejection
  • Graft versus host disease [33]
  • Necrotizing enterocolitis
  • Pancreatitis
  • Pulmonary embolism
  • Viral encephalitis

Future and Controversies

Current state of intestinal transplantation

Most recipients of intestinal transplants are free from TPN and enjoy an excellent quality of life. Intestinal transplantation has matured into a life-saving and cost-effective therapy for patients with intestinal failure.[34] Rejection and infection are still the 2 most perplexing problems surrounding intestinal and multivisceral transplantation. Earlier patient referral, the development of new immunosuppressive agents, and the discovery of a serum marker for graft rejection are the keys to continued improvements in graft and patient survival rates.

Evolution and future directions

Since 1998, the authors have been changing many things, such as surgical technique, CMV prophylaxis, rejection monitoring with ZVE, new immunosuppression, and prevention of overimmunosuppression. These changes have contributed to the recent improvement in the survival rate.

Systemic drainage to the inferior vena cava has been applied, and results are satisfactory. Metabolic effect and survival rates are the same as for portal drainage. CMV-positive donors are used safely with intense CMV prophylaxis by CytoGam. Rejection monitoring with ZVE prevents the delay of the diagnosis of the rejection and overimmunosuppression. Zenapax, rapamycin, and Campath are ongoing new immunosuppression therapies. These evolutions have improved the results of intestinal transplantation since 1998. New findings from basic research may contribute to the improvement of small bowel transplantation.

Enterocytes have been studied at the University of Miami hospital. The study demonstrated the presence of host-derived (male) enterocytes in the intestinal allografts (female). The presence of male crypt cells and male enterocytes in the intestinal grafts suggested that they probably originated from circulating stem cells and that the differentiation process might have progressed from crypt cells to mature enterocytes. Generating enterocytes from a patient's own stem cells may be possible; this might assist in developing novel strategies to increase intestinal absorptive surface and repair and to engineer neointestines for patients with short bowel syndrome.

The authors' clinical study also demonstrated some promising preliminary data about serum citrulline as a marker for early acute cellular rejection after intestinal transplantation. These findings might help the rejection monitoring.

Newer immunosuppressive medications with more specific actions, further advancement of rejection monitoring, and infection control are urgently required. Continuing efforts will

contribute to future success.

Antibody-mediated humoral rejection may play an important role of intestinal transplantation. New studies have been started to clarify the relation between the antibody and rejection.

Contributor Information and Disclosures

Seigo Nishida, MD, PhD Professor of Clinical Surgery, Miami Transplant Institute, Department of Surgery, University of Miami, Leonard M Miller School of Medicine

Seigo Nishida, MD, PhD is a member of the following medical societies: American College of Surgeons, American Society of Transplant Surgeons, Society for Surgery of the Alimentary Tract, Society of University Surgeons, Transplantation Society, Japan Surgical Society

Disclosure: Nothing to disclose.


G Patricia Cantwell, MD, FCCM Professor of Clinical Pediatrics, Chief, Division of Pediatric Critical Care Medicine, University of Miami Leonard M Miller School of Medicine/ Holtz Children's Hospital, Jackson Memorial Medical Center; Medical Director, Palliative Care Team, Holtz Children's Hospital; Medical Manager, FEMA, South Florida Urban Search and Rescue, Task Force 2

G Patricia Cantwell, MD, FCCM is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Heart Association, American Trauma Society, National Association of EMS Physicians, Society of Critical Care Medicine, Wilderness Medical Society

Disclosure: Nothing to disclose.

Andreas G Tzakis, MD, PhD Professor of Surgery

Andreas G Tzakis, MD, PhD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Angiology, American College of Surgeons, American Medical Association, American Society of Transplant Surgeons, American Spinal Injury Association, International College of Surgeons, Society of University Surgeons

Disclosure: Nothing to disclose.

Tomoaki Kato, MD Associate Professor of Clinical Surgery, Department of Surgery, Division of Liver and Gastrointestinal Transplantation, Miller School of Medicine, University of Miami

Tomoaki Kato, MD is a member of the following medical societies: American Gastroenterological Association, American Medical Association, American Society of Transplant Surgeons

Disclosure: Nothing to disclose.

David M Levi, MD Professor of Clinical Surgery, Department of Surgery, Division of Liver and Gastrointestinal Transplantation, Division of General Surgery, Jackson Memorial Hospital, Miller School of Medicine, University of Miami

David M Levi, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Study of Liver Diseases, American College of Surgeons, American Society of Transplant Surgeons, Phi Beta Kappa, International Liver Transplantation Society, Transplantation Society

Disclosure: Nothing to disclose.

Jose R Nery, MD Medical Director, Good Samaritan Community Health Care Center

Jose R Nery, MD is a member of the following medical societies: American Society of Transplant Surgeons, International Liver Transplantation Society, Transplantation Society

Disclosure: Nothing to disclose.

Juan Madariaga, MD 

Juan Madariaga, MD is a member of the following medical societies: American Medical Association, American Society of Transplant Surgeons, Medical Society of the State of New York, Society of Surgical Oncology

Disclosure: Nothing to disclose.

Phillip Ruiz, Jr, MD, PhD Professor of Pathology, Department of Pathology and Surgery, Miller School of Medicine, University of Miami

Phillip Ruiz, Jr, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American Society for Clinical Pathology, American Society of Nephrology, American Society of Transplant Surgeons, American Society of Transplantation, Clinical Immunology Society, Florida Medical Association, New York Academy of Sciences, Pan America Medical Association of Central Florida, Southern Medical Association, United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Brian F Gilchrist, MD Surgeon-in-Chief of Pediatric Surgery, The Floating Hospital for Children at Tufts-New England Medical Center; Associate Professor, Department of Surgery, Tufts University School of Medicine

Brian F Gilchrist, MD is a member of the following medical societies: American College of Surgeons, American Pediatric Surgical Association, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

Chief Editor

Stuart M Greenstein, MD Professor of Surgery, Albert Einstein College of Medicine; Consulting Surgeon, Department of Surgery, Division of Transplantation, Montefiore Medical Center

Stuart M Greenstein, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Surgeons, American Society of Transplant Surgeons, American Society of Transplantation, Association for Academic Surgery, International College of Surgeons, Medical Society of New Jersey, National Kidney Foundation, New York Academy of Sciences, Southeastern Surgical Congress

Disclosure: Nothing to disclose.

Additional Contributors

Casimir F Firlit, MD, PhD Director of Reconstructive Urology, Neuro-Urology and Fetal Urology at SSM Cardinal Glennon Children's Medical Center.

Casimir F Firlit, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Medical Association, American Society of Transplant Surgeons, American Urological Association, Illinois State Medical Society

Disclosure: Nothing to disclose.


John F Thompson, MD Professor of Pediatrics, Director of Division of Pediatric Gastroenterology and Nutrition, University of Miami Miller School of Medicine

John F Thompson, MD is a member of the following medical societies: Alpha Omega Alpha, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.


The authors gratefully acknowledge Jose Martinez, MD, for his support involving endoscopy and patient care. The authors also acknowledge Joseph Tector, MD, for his support of this manuscript. The authors would also like to thank Debbie Weppler, RN, for her contribution of intestinal patient management and data collection.

  1. Carrel A. La technique operatoire des anastomoses vasculaires et la transplantation des visceres. Lyon MEO. 1902. 98:859.

  2. Lillehei RC, Goott B, Miller FA. The physiological response of the small bowel of the dog to ischemia including prolonged in vitro preservation of the small bowel with successful replacement and survival. Ann Surg. 1959. 150:543-60.

  3. Starzl TE, Kaupp HA Jr. Mass homotransplantation of abdominal organs in dogs. Surg Forum. 1960. 11:28-30.

  4. Lillehei RC, Idezuki Y, Feemster JA, et al. Transplantation of stomach, intestine, and pancreas: experimental and clinical observations. Surgery. 1967 Oct. 62(4):721-41. [Medline].

  5. Okumura M, Mester M. The coming of age of small bowel transplantation: a historical perspective. Transplant Proc. 1992 Jun. 24(3):1241-2. [Medline].

  6. Grant D, Duff J, Zhong R, et al. Successful intestinal transplantation in pigs treated with cyclosporine. Transplantation. 1988 Feb. 45(2):279-84. [Medline].

  7. Starzl TE, Rowe MI, Todo S. Transplantation of multiple abdominal viscera. JAMA. 1989 Mar 10. 261(10):1449-57. [Medline].

  8. Grant D, Wall W, Mimeault R, et al. Successful small-bowel/liver transplantation. Lancet. 1990 Jan 27. 335(8683):181-4. [Medline].

  9. Todo S, Tzakis AG, Abu-Elmagd K, et al. Intestinal transplantation in composite visceral grafts or alone. Ann Surg. 1992 Sep. 216(3):223-33; discussion 233-4. [Medline].

  10. Todo S, Tzakis A, Abu-Elmagd K, et al. Current status of intestinal transplantation. Adv Surg. 1994. 27:295-316. [Medline].

  11. Tzakis A, Webb M, Nery J, et al. Experience with intestinal transplantation at the University of Miami. Transplant Proc. 1996 Oct. 28(5):2748-9. [Medline].

  12. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation. 2003 May 15. 75(9):1512-7. [Medline].

  13. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May. 186(5):512-25; discussion 525-7. [Medline].

  14. Langnas AN, Shaw BW Jr, Antonson DL, et al. Preliminary experience with intestinal transplantation in infants and children. Pediatrics. 1996 Apr. 97(4):443-8. [Medline].

  15. Weih S, Kessler M, Fonouni H, et al. Current practice and future perspectives in the treatment of short bowel syndrome in children-a systematic review. Langenbecks Arch Surg. 2011 Nov 22. [Medline].

  16. Wallander J, Ewald U, Läckgren G, Tufveson G, Wahlberg J, Meurling S. Extreme short bowel syndrome in neonates: an indication for small bowel transplantation?. Transplant Proc. 1992 Jun. 24(3):1230-5. [Medline].

  17. DeLegge M, Alsolaiman MM, Barbour E, Bassas S, Siddiqi MF, Moore NM. Short bowel syndrome: parenteral nutrition versus intestinal transplantation. Where are we today?. Dig Dis Sci. 2007 Apr. 52(4):876-92. [Medline].

  18. Quigley EM. Small intestinal transplantation: reflections on an evolving approach to intestinal failure. Gastroenterology. 1996 Jun. 110(6):2009-12. [Medline].

  19. Abu-Elmagd K, Fung J, Bueno J, et al. Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann Surg. 2000 Nov. 232(5):680-7. [Medline].

  20. Park YS, Oh JY, Hwang BY, Moon Y, Lee HM, Hwang GS. Prolonged post-reperfusion syndrome during multivisceral organ transplantation in a pediatric patient: a case report. Korean J Anesthesiol. 2014 Jun. 66(6):467-71. [Medline]. [Full Text].

  21. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994 Jul 15. 78(1):35-43. [Medline].

  22. Foster PF, Sankary HN, McChesney L, et al. Cytomegalovirus infection in the composite liver/intestinal/pancreas allograft. Transplant Proc. 1996 Oct. 28(5):2742-3. [Medline].

  23. Nishida S, Levi DM, Moon JI, et al. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients. Transplant Proc. 2006 Jul-Aug. 38(6):1747-9. [Medline].

  24. Kato T, O'Brien CB, Nishida S, et al. The first case report of the use of a zoom videoendoscope for the evaluation of small bowel graft mucosa in a human after intestinal transplantation. Gastrointest Endosc. 1999 Aug. 50(2):257-61. [Medline].

  25. Pappas PA, Tzakis AG, Saudubray JM. Trends in serum citrulline and acute rejection among recipients of small bowel transplants. Transplant Proc. 2004 Mar. 36(2):345-7. [Medline].

  26. Tsai HL, Island ER, Chang JW, Gonzalez-Pinto I, Tryphonopoulos P, Nishida S. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation. 2011 Sep 27. 92(6):709-15. [Medline].

  27. Grant D. Intestinal transplantation: 1997 report of the international registry. Intestinal Transplant Registry. Transplantation. 1999 Apr 15. 67(7):1061-4. [Medline].

  28. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature. 1969 Aug 2. 223(205):472-6. [Medline].

  29. Reyes J, Bueno J, Kocoshis S, et al. Current status of intestinal transplantation in children. J Pediatr Surg. 1998 Feb. 33(2):243-54. [Medline].

  30. Horslen SP, Kaufman SS, Sudan DL. Isolated liver transplantation in infants with total parenteral nutrition-associated end-stage liver disease. Transplant Proc. 2000 Sep. 32(6):1241. [Medline].

  31. Asfar S, Atkison P, Ghent C, et al. Small bowel transplantation. A life-saving option for selected patients with intestinal failure. Dig Dis Sci. 1996 May. 41(5):875-83. [Medline].

  32. Trevizol AP, David AI, Yamashita ET, Pecora RA, D'Albuquerque LA. Intestinal and multivisceral retransplantation results: literature review. Transplant Proc. 2013 Apr. 45(3):1133-6. [Medline].

  33. Feito-Rodríguez M, de Lucas-Laguna R, Gómez-Fernández C, Sendagorta-Cudós E, Collantes E, Beato MJ, et al. Cutaneous graft versus host disease in pediatric multivisceral transplantation. Pediatr Dermatol. 2013 May-Jun. 30(3):335-41. [Medline].

  34. Abu-Elmagd KM, Reyes J, Fung JJ, et al. Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Transplant Proc. 1999 Feb-Mar. 31(1-2):582-4. [Medline].

  35. Casavilla A, Selby R, Abu-Elmagd K, et al. Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg. 1992 Nov. 216(5):605-9. [Medline].

  36. Deltz E, Mengel W, Hamelmann H. Small bowel transplantation: report of a clinical case. Prog Pediatr Surg. 1990. 25:90-6. [Medline].

  37. Garcia M, Weppler D, Mittal N. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc. 2004 Mar. 36(2):323-4. [Medline].

  38. Goulet O, Revillon Y, Canioni D, et al. Two and one-half-year follow-up after isolated cadaveric small bowel transplantation in an infant. Transplant Proc. 1992 Jun. 24(3):1224-5. [Medline].

  39. Reyes J, Todo S, Bueno J, et al. Intestinal transplantation in children: five-year experience. Transplant Proc. 1996 Oct. 28(5):2755-6. [Medline].

Isolated intestine transplantation.
Liver and intestine transplantation.
Liver, intestine, and pancreas transplantation.
Multivisceral transplantation.
Endoscopic view of small-bowel graft is shown. Views A and D are normal; views B and E show moderate rejection; and views C and F indicate severe rejection.
Number of transplants.
Intestinal transplantation in adult and pediatric patients.
Donor age.
Patient survival of isolated intestinal transplantation.
Patient survival of 3 types of intestinal transplantation.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.